This site is intended for healthcare professionals

Bristol Myers Squibb shares research supporting correlation between New York Heart Association Functional Class (NYHA class) and mortality in obstructive hypertrophic cardiomyopathy.

Read time: 1 mins
Last updated:11th Sep 2021
Published:11th Sep 2021
Bristol Myers Squibb announced findings from a global real-world evidence study that the risk of mortality increases with worse New York Heart Association functional class (NYHA class) for patients with obstructive hypertrophic cardiomyopathy (obstructi ve HCM). While other studies have documented this association in HCM, this study represents one of the largest, multi-centered studies that specifically focuses on the obstructive HCM patient population.
Condition: Hypertrophic Cardiomyopathy
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest